IgG4相关肾病早期肾功能改善与患者生存、肾脏结局及糖皮质激素相关并发症的关系
该研究回顾性分析了95例IgG4相关肾病患者,中位随访71个月,评估长期肾脏预后、恶性肿瘤、糖皮质激素毒性及死亡情况。结果显示,治疗开始后3个月内最佳eGFR与较低死亡风险(HR 0.67)和较少严重感染(HR 0.63)相关;治疗开始时eGFR(HR 0.71)和广泛纤维化(HR 2.58)显著影响进展至CKD的时间。
要点
- 治疗开始后3个月内最佳eGFR越高,死亡和严重感染风险越低。
- 治疗开始时eGFR较低和广泛纤维化是进展至CKD的独立危险因素。
- 随访期间68%患者发生CKD,17%出现eGFR下降>30%,3%进展至ESRD。
核心结论
- 通过早期治疗实现更多肾功能恢复可能改善IgG4相关肾病患者的生存、肾脏结局及部分糖皮质激素相关并发症。
研究设计与样本
- 回顾性队列研究,纳入95例IgG4相关肾病患者,中位随访71个月。
主要发现
- 诊断时中位eGFR为46 ml/min per 1.73 m2。
- 随访期间68%患者发生CKD,17%出现eGFR下降>30%,3%进展至ESRD。
- 年龄和性别校正Cox回归显示,治疗开始时eGFR(HR 0.71)和广泛纤维化(HR 2.58)显著影响进展至CKD的时间。
- 10例患者死亡,标准化死亡比为0.94;恶性肿瘤的标准化发病率为1.52;严重感染发生率为1.80/100人年。
- 治疗开始后3个月内最佳eGFR与较低死亡风险(HR 0.67)和较少严重感染(HR 0.63)相关。
临床怎么用
- 对IgG4相关肾病患者应尽早开始治疗,以争取肾功能恢复,可能改善生存和减少感染等并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We aimed to clarify long-term renal prognosis, complications of malignancy, glucocorticoid (GC) toxicity, and mortality in immunoglobulin G4 (IgG4)-related kidney disease (IgG4-RKD). METHODS: Reviewing the medical records of 95 patients with IgG4-RKD, we investigated clinical and pathologic features at baseline, the course of renal function, complications of malignancy, GC toxicity, and mortality during follow-up (median 71 months). The standardized incidence ratio (SIR) of malignancy and standardized mortality ratio were calculated using national statistics. Factors related to outcomes were assessed by Cox regression analyses. RESULTS: At diagnosis, the median estimated glomerular infiltration rate (eGFR) was 46 ml/min per 1.73 m2. GC achieved initial improvement. Additional renal function recovery within 3-months of initial treatment occurred in patients with highly elevated serum IgG and IgG4 levels and hypocomplementemia. During follow-up, 68%, 17%, and 3% of the patients had chronic kidney disease (CKD), >30% eGFR decline, and end-stage renal disease (ESRD), respectively. Age-adjusted and sex-adjusted Cox regression analyses indicated that eGFR (hazard ratio [HR], 0.71) and extensive fibrosis (HR, 2.58) at treatment initiation had a significant impact on the time to CKD. Ten patients died, and the standardized mortality ratio was 0.94. The SIR of malignancy was 1.52. The incidence rate (IR) of severe infection was 1.80/100 person-years. Cox regression analyses showed that the best eGFR within 3 months after treatment initiation were associated with lower mortality (HR 0.67) and fewer severe infections (HR 0.63). CONCLUSION: This study suggests that more renal function recovery through early treatment initiation may improve patient survival, renal outcomes, and some GC-related complications in IgG4-RKD.
引用
- Mizushima I, Saeki T, Kobayashi D, et al. Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in Japan. Kidney Int Rep. 2023. PMID: 38312790. doi:10.1016/j.ekir.2023.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。